Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kalidas Sahetya

Interventional Cardiology Bowling Green, KY Medical Doctor

NPI 1649258088 CMS profile 165548

427 US 31W Byp, Bowling Green, KY 42101

Open in the dashboard

General payments

$6,232

303 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kalidas Sahetya of Bowling Green, KY is reported in the CMS Open Payments database as having received $6,232 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $630 32
2023 General $1,072 63
2022 General $1,235 65
2021 General $1,252 69
2020 General $338 23
2019 General $1,706 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kalidas Sahetya
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Kalidas Sahetya were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Kalidas Sahetya Interventional Cardiology median Middle half National median
2019 $1,706 $1,097 $329–$3,048 $163
2020 $338 $473 $161–$1,480 $114
2021 $1,252 $677 $233–$1,827 $132
2022 $1,235 $978 $333–$2,724 $149
2023 $1,072 $1,136 $382–$2,986 $160
2024 $630 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Janssen Pharmaceuticals, Inc $1,486 79 payments
  2. Terumo Medical Corporation $925 7 payments
  3. Novartis Pharmaceuticals Corporation $563 41 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $530 36 payments
  5. Pfizer Inc. $332 22 payments
  6. Sanofi-Aventis U.S. LLC $319 18 payments
  7. Actelion Pharmaceuticals US, Inc. $200 6 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $197 10 payments
  9. Amgen Inc. $162 9 payments
  10. AstraZeneca Pharmaceuticals LP $158 10 payments
  11. Other $1,361 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,234 297 payments
  2. Travel and Lodging $808 4 payments
  3. Education $190 2 payments
Products named General payments · program years 2019–2024
  1. XARELTO $1,486 79 payments
  2. Glidesheath $925 7 payments
  3. TR Band $925 7 payments
  4. Heartrail $898 5 payments
  5. Optitorque $898 5 payments
  6. LifeVest $530 36 payments
  7. LEQVIO $296 25 payments
  8. ELIQUIS $276 18 payments
  9. PAXLOVID $208 14 payments
  10. ENTRESTO $194 12 payments
  11. Other $2,959 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

490

Median for Interventional Cardiology: 2,236

Drug cost

$72,469

Median for Interventional Cardiology: $380,412

Branded share of claims

25.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 51 $44,750
Multaq Dronedarone Hcl Brand 11 $10,781
Brilinta Ticagrelor Brand 14 $9,567
Dofetilide Generic 22 $3,720
Metoprolol Succinate Generic 55 $518
Ranolazine Er Ranolazine Brand 14 $460
Amiodarone Hcl Generic 18 $451
Nitroglycerin Generic 34 $415
Potassium Chloride Generic 19 $398
Atorvastatin Calcium Generic 29 $216

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$219,184

Of which drugs: $2,268

Medicare patients

680

Average age 76

Services billed

4,502

312 women, 368 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Arthritis 48%
Atrial fibrillation 44%
Heart failure 42%
Diabetes 40%
COPD 35%
Chronic kidney disease 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 63 252 $1,984

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $140
$140 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $129
$129 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $118
$118 — —
ELIQUIS
  • PFIZER INC. $16
$16 51 —
NURTEC ODT
  • PFIZER INC. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record